The short version of LC-MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-18. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
=== Norbornene cycloaddition === 1,3 dipolar cycloadditions have been developed as a bioorthogonal reaction using a nitrile oxide as a 1,3-dipole and a norbornene as a dipolarophile. Its primary use has been in labeling DNA and RNA in automated oligonucleotide synthesizers, and polymer crosslinking in the presence of living cells.
== Discontinued operations == In 1998, Dairy Farm sold out its 49% interest in Nestlé Dairy Farm, set up in 1992 to develop dairy products factories throughout China, to Nestlé; on the merger of Kwik Save with Somerfield, Dairy Farm sold its 11% holding for US$290 million. Dairy Farm acquired 25% of the "No Frills" Kwik Save Group in 1987; Sold the 108-store Simago chain in Spain acquired in 1990. In March 2000, Dairy Farm sold its half share in DFI Géant, the Taiwan hypermarket opened in 1998 back to Casino, its joint venture partner. In 2001, the company sold the 287-store Franklins chain in Australia which it acquired in 1978. Its Hong Kong–based distribution business, Sims Trading, was sold to CITIC Pacific. In June 2002, the 61-store Woolworths chain in New Zealand acquired in 1990, was sold for US$337 million. In 2004, the Group's Hong Kong ice manufacturing business which began in 1918 was sold for US$107 million. In 2023, the Group's Malaysian food retailing business was sold to Macrovalue Sdn Bhd On 19 April 2024, DFI's subsidiary PT Hero Supermarket Tbk announced it would divest its supermarket businesses along with the rights to the Hero brand to PT Hero Retail Nusantara for 135 billion rupiahs. In 2025, DFI Retail Group in Singapore announced the sale of its food retail operations (Cold Storage, CS Fresh, Jasons Deli, and Giant) to Malaysian-based Macrovalue for S$125 million.
=== Forming protein-protein conjugates via Cu-free click chemistry === Studies have explored the strategy of producing protein-protein conjugates with the help of the aldehyde tag. Their aim was to connect full length human IgG (hIgG) to the human growth hormone (hGH). These protein-protein conjugates can be superior to monomeric proteins in terms of serum half life in protein therapeutics and, additionally, have appealing dual binding properties. In order to achieve protein fusion, the five-residue aldehyde tag (CxPxR) was incooperated into hIgG and hGH. In hIgG, the aldehyde tag was introduced at the C termini of the two heavy chains, resulting in two possible conjugation sites. FGE then oxidizes the cysteine residue to formylglycine (fGly) during protein expression. For the subsequent conjugation steps, the strategy of the copper-free click chemistry was selected. A strain-promoted 1,3-dipolar cycloaddition of a cyclooctynes and an azide was carried out forming a covalent linkage (also termed the Cu-free azide-alkyne cycloaddition). Thus, the aldehyde bearing proteins react under oxime formation with different heterobifunctional linkers which carry an aminooxy residue on one end and either an azide or cyclooctynes on the other. This results in the attachment of hIgG to a linker containing a cyclooctyne (here dibenzoazacyclooctyne (DIBAC)) and hGH to a linker holding an azide function (Fig.: 2A and B). The proteins hGH and hIgG were also treated with DIBAC-488, azide Alexa Fluor 647 and analysed by SDS-PAGE and Western blot to validate oxime formation.
In late August 2013, Starbucks announced its first store in Colombia at a press conference in Bogotá, where the company's CEO explained, "Starbucks has always admired and respected Colombia's distinguished coffee tradition." In May 2014, Starbucks announced its first café in Bolivia would open in 2014 in Santa Cruz de la Sierra and the first in Panama in 2015. In January 2016, Starbucks announced that it would launch operation in Trinidad and Tobago. On August 29, 2016, Starbucks opened its first store at South Park Mall in San Fernando. In November 2017, Starbucks commenced operations in Jamaica, where the first store opened in the resort city of Montego Bay on the shores of the Doctor's Cave Beach Club, offering views of the Caribbean Sea. The company also reaffirmed its commitment to working with local coffee farmers to "implement systems to increase productivity and yields, while also increasing compliance to international standards". Starbucks Jamaica opened its first store on November 21, 2017, with plans to open 15 locations island-wide over a 5-year period. Starbucks Jamaica opened stores at the Sangster International Airport in Montego Bay and at the Falmouth Pier, in Falmouth, Jamaica. Starbucks Jamaica announced plans to open up to six stores in Kingston, Jamaica, by 2019. The first of the Kingston stores opened on June 21, 2018. The second store is in Kingston's central business district, New Kingston.
== Medical career == Farthing began his medical career in New Zealand where he practiced as a dermatologist. After five years, he moved abroad and worked for a year in Riyadh, Saudi Arabia. He then moved to England and joined St. Stephen's Hospital, London in Chelsea. Between 1985 and 1987, the numbers of AIDS patients treated at St Stephen's rose from a dozen to over 1000. From 1985 to 1988, he was involved in clinical trials for the antiretroviral drugs Thymosin, AZT and foscarnet. In 1987, he helped found the Kobler Center at St Stephen's Hospital which specialised in the treatment and research of HIV/AIDS. It was one of the first wards in the United Kingdom to specialise in the area. He was chair of the all-party parliamentary committee on AIDS during the late 1980s, and was instrumental in guiding the governments reaction to the AIDS crisis. In 1988, he was awarded a Churchill fellowship which allowed him to move to the United States of America where he studied AIDS at the Bellevue Hospital in New York. He later became the director of the hospital's AIDS treatment program. In 1994, he moved to Los Angeles where he became the principal investigator of the AIDS Healthcare Foundation, and in 2001, he was promoted to medical director. In 2007, he left the United States for Hong Kong where he joined Merck Sharp & Dohme. At the time of his death, he was director of medical affairs for infectious diseases in the Asia-Pacific.
Sources: en.wikipedia.org
=== Drawing paste === In the United Kingdom, a medication containing magnesium sulfate, called "drawing paste", is claimed to be useful for small boils or localised infections, and removing splinters. The standard British Pharmacopoeia composition is dried magnesium sulfate 47.76% (by mass), phenol 0.49%, and glycerol to balance.
=== 1975 === January 3: The Trade Act of 1974, including the Jackson–Vanik amendment, is signed into law in the United States. April 13: Tensions between the Maronite Christians and Muslims ignited the Lebanese Civil War. April 18: The communist Khmer Rouge, under the leadership of Pol Pot, take power in Cambodia. Beginning of the Cambodian genocide. April 30: North Vietnam wins the Vietnam War. The South Vietnam regime falls with the surrender of Saigon and the two countries are later united under a communist government. May 12: Mayagüez incident: the Khmer Rouge seize an American naval ship, prompting American intervention to recapture the ship and its crew. In the end, the crew is released from captivity. June 8: Venera 9, a Soviet uncrewed space mission to Venus, is launched. June 25: Portugal withdraws from Angola and Mozambique, where Marxist governments are installed, the former with backing from Cuban troops. Civil war engulfs both nations and involves Angolans, Mozambicans, South Africans, and Cubans, with the superpowers supporting their respective ideologies. July 5: Cape Verde becomes independent from Portugal. July 6: Comoros becomes independent from France. July 12: São Tomé and Príncipe becomes independent from Portugal. July 15: The Apollo-Soyuz Test Project takes place. It is the first joint flight of the US and Soviet space programs. The mission is seen as a symbol of détente and an end to the "space race".
The classic symptom of keratoconus is the perception of multiple "ghost" images, known as monocular polyopia. This effect is most clearly seen with a high contrast field, such as a point of light on a dark background. Instead of seeing just one point, a person with keratoconus sees many images of the point, spread out in a chaotic pattern. This pattern does not typically change from day to day, but over time, it often takes on new forms. People also commonly notice streaking and flaring distortion around light sources. Some even notice the images moving relative to one another in time with their heartbeat. The predominant optical aberration of the eye in keratoconus is coma. The visual distortion experienced by the person comes from two sources, one being the irregular deformation of the surface of the cornea, and the other being scarring that occurs on its exposed highpoints. These factors act to form regions on the cornea that map an image to different locations on the retina. The effect can worsen in low light conditions, as the dark-adapted pupil dilates to expose more of the irregular surface of the cornea. Significant retinal layer thickness reduction is observed in keratoconus, especially in younger patients (<30 years).
O-thiocarbamates (2), ROC(=S)NR2, where the carbonyl group (C=O) is replaced with a thiocarbonyl group (C=S) S-thiocarbamates (3), RSC(=O)NR2, where the R–O– group is replaced with an R–S– group O-thiocarbamates can isomerise to S-thiocarbamates, for example in the Newman–Kwart rearrangement.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.